4-phenylbutylamine has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, W; Bai, Z; Chen, W; Guo, M; Su, Y; Wang, W; Wu, J | 1 |
| Chen, X; Lan, L; Lin, B; Luo, H; Su, L; Wu, J; Zhang, H | 1 |
2 other study(ies) available for 4-phenylbutylamine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Depletion and Reversal of Hepatocellular Carcinoma Inducing CTL through ER Stress-Dependent PERK-CHOP Signaling Pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; eIF-2 Kinase; Granzymes; Hepatitis A Virus Cellular Receptor 2; Humans; Liver Neoplasms; Mice; Mice, Inbred Strains; Mucins; Perforin; Polyphenols; Programmed Cell Death 1 Receptor; Signal Transduction; T-Lymphocytes, Cytotoxic; Tea; Transcription Factor CHOP; Tunicamycin | 2022 |
Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Butylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Flavonoids; Heat-Shock Proteins; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; Transcription Factor CHOP | 2013 |